Relapsed or refractory AL amyloidosis research hub

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis

This study is looking at a new treatment called belantamab mafodotin for people with AL amyloidosis that has come back or isn't getting better. Researchers want to see how well it works and if it's safe after 6 months by checking for improvements in the disease.